S&P 500   4,595.74 (+0.63%)
DOW   34,593.80 (+0.32%)
QQQ   396.58 (+0.70%)
AAPL   169.54 (+2.57%)
MSFT   336.84 (+1.89%)
FB   317.94 (-2.01%)
GOOGL   2,885.44 (+1.67%)
AMZN   3,508.13 (+0.03%)
TSLA   1,143.36 (-0.12%)
NVDA   325.60 (-0.36%)
BABA   124.80 (-2.14%)
NIO   39.59 (+1.18%)
CGC   10.36 (-3.27%)
AMD   154.88 (-2.20%)
GE   95.60 (+0.64%)
MU   87.69 (+4.39%)
T   22.58 (-1.10%)
F   20.00 (+4.22%)
DIS   145.20 (+0.21%)
PFE   54.49 (+1.41%)
ACB   6.26 (-2.49%)
AMC   32.66 (-3.77%)
BA   194.52 (-1.68%)
S&P 500   4,595.74 (+0.63%)
DOW   34,593.80 (+0.32%)
QQQ   396.58 (+0.70%)
AAPL   169.54 (+2.57%)
MSFT   336.84 (+1.89%)
FB   317.94 (-2.01%)
GOOGL   2,885.44 (+1.67%)
AMZN   3,508.13 (+0.03%)
TSLA   1,143.36 (-0.12%)
NVDA   325.60 (-0.36%)
BABA   124.80 (-2.14%)
NIO   39.59 (+1.18%)
CGC   10.36 (-3.27%)
AMD   154.88 (-2.20%)
GE   95.60 (+0.64%)
MU   87.69 (+4.39%)
T   22.58 (-1.10%)
F   20.00 (+4.22%)
DIS   145.20 (+0.21%)
PFE   54.49 (+1.41%)
ACB   6.26 (-2.49%)
AMC   32.66 (-3.77%)
BA   194.52 (-1.68%)
S&P 500   4,595.74 (+0.63%)
DOW   34,593.80 (+0.32%)
QQQ   396.58 (+0.70%)
AAPL   169.54 (+2.57%)
MSFT   336.84 (+1.89%)
FB   317.94 (-2.01%)
GOOGL   2,885.44 (+1.67%)
AMZN   3,508.13 (+0.03%)
TSLA   1,143.36 (-0.12%)
NVDA   325.60 (-0.36%)
BABA   124.80 (-2.14%)
NIO   39.59 (+1.18%)
CGC   10.36 (-3.27%)
AMD   154.88 (-2.20%)
GE   95.60 (+0.64%)
MU   87.69 (+4.39%)
T   22.58 (-1.10%)
F   20.00 (+4.22%)
DIS   145.20 (+0.21%)
PFE   54.49 (+1.41%)
ACB   6.26 (-2.49%)
AMC   32.66 (-3.77%)
BA   194.52 (-1.68%)
S&P 500   4,595.74 (+0.63%)
DOW   34,593.80 (+0.32%)
QQQ   396.58 (+0.70%)
AAPL   169.54 (+2.57%)
MSFT   336.84 (+1.89%)
FB   317.94 (-2.01%)
GOOGL   2,885.44 (+1.67%)
AMZN   3,508.13 (+0.03%)
TSLA   1,143.36 (-0.12%)
NVDA   325.60 (-0.36%)
BABA   124.80 (-2.14%)
NIO   39.59 (+1.18%)
CGC   10.36 (-3.27%)
AMD   154.88 (-2.20%)
GE   95.60 (+0.64%)
MU   87.69 (+4.39%)
T   22.58 (-1.10%)
F   20.00 (+4.22%)
DIS   145.20 (+0.21%)
PFE   54.49 (+1.41%)
ACB   6.26 (-2.49%)
AMC   32.66 (-3.77%)
BA   194.52 (-1.68%)
NASDAQ:MOR

MorphoSys Stock Forecast, Price & News

$10.03
-0.08 (-0.79%)
(As of 12/1/2021 01:08 PM ET)
Add
Compare
Today's Range
$10.03
$10.14
50-Day Range
$9.69
$12.45
52-Week Range
$9.47
$30.75
Volume
197 shs
Average Volume
75,356 shs
Market Capitalization
$1.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.99
30 days | 90 days | 365 days | Advanced Chart
Receive MOR News and Ratings via Email

Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter.


MorphoSys logo

About MorphoSys

MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications. It operates through the Proprietary Development and Partnered Discovery segments. The Proprietary Development segment combines proprietary research and development of therapeutic compounds. The Partnered Discovery segment offers technologies to make human antibody-based therapeutics on behalf of partners in the pharmaceutical industry. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.

Headlines

MorphoSys AG: Corporate Calendar 2022
November 29, 2021 |  uk.finance.yahoo.com
Corporate Calendar 2022
November 29, 2021 |  ca.finance.yahoo.com
DGAP-News: MorphoSys AG: Corporate Calendar 2022
November 29, 2021 |  markets.businessinsider.com
MorphoSys (NASDAQ:MOR) Shares Gap Up to $9.69
November 24, 2021 |  americanbankingnews.com
MorphoSys (NASDAQ:MOR) Reaches New 1-Year Low at $9.56
November 23, 2021 |  americanbankingnews.com
MorphoSys (NASDAQ:MOR) Shares Gap Down to $10.45
November 22, 2021 |  americanbankingnews.com
MorphoSys (NASDAQ:MOR) Sets New 1-Year Low at $10.69
November 17, 2021 |  americanbankingnews.com
MorphoSys' (MOR) Overweight Rating Reaffirmed at Morgan Stanley
November 12, 2021 |  americanbankingnews.com
MorphoSys (NASDAQ:MOR) Reaches New 1-Year Low at $10.76
November 11, 2021 |  americanbankingnews.com
MorphoSys AG: MorphoSys Announces Departure of Roland Wandeler
November 11, 2021 |  finanznachrichten.de
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MOR
Employees
615
Year Founded
N/A

Sales & Book Value

Annual Sales
$374.30 million
Cash Flow
$0.93 per share
Book Value
$5.39 per share

Profitability

Net Income
$111.82 million
Pretax Margin
-123.93%

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$1.37 billion
Optionable
Not Optionable

Company Calendar

Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/21/2022

MarketRank

Overall MarketRank

1.22 out of 5 stars

Medical Sector

1188th out of 1,392 stocks

Pharmaceutical Preparations Industry

567th out of 669 stocks

Analyst Opinion: 3.2Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












MorphoSys (NASDAQ:MOR) Frequently Asked Questions

Is MorphoSys a buy right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last twelve months. There are currently 9 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MorphoSys stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MOR, but not buy additional shares or sell existing shares.
View analyst ratings for MorphoSys
or view top-rated stocks.

How has MorphoSys' stock been impacted by Coronavirus (COVID-19)?

MorphoSys' stock was trading at $25.26 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MOR stock has decreased by 60.3% and is now trading at $10.03.
View which stocks have been most impacted by COVID-19
.

Are investors shorting MorphoSys?

MorphoSys saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 203,100 shares, an increase of 34.7% from the October 31st total of 150,800 shares. Based on an average daily trading volume, of 61,200 shares, the days-to-cover ratio is presently 3.3 days.
View MorphoSys' Short Interest
.

When is MorphoSys' next earnings date?

MorphoSys is scheduled to release its next quarterly earnings announcement on Monday, March 21st 2022.
View our earnings forecast for MorphoSys
.

What guidance has MorphoSys issued on next quarter's earnings?

MorphoSys updated its FY 2021 earnings guidance on Wednesday, December, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $182.78 million-$212.26 million, compared to the consensus revenue estimate of $197.31 million.

What price target have analysts set for MOR?

13 brokerages have issued twelve-month price targets for MorphoSys' stock. Their forecasts range from $12.00 to $59.00. On average, they expect MorphoSys' stock price to reach $25.46 in the next year. This suggests a possible upside of 153.8% from the stock's current price.
View analysts' price targets for MorphoSys
or view top-rated stocks among Wall Street analysts.

Who are MorphoSys' key executives?

MorphoSys' management team includes the following people:
  • Jean-Paul Kress, CEO & Chairman-Management Board
  • Roland Wandeler, Chief Operating Officer
  • Sung H. Lee, Chief Financial Officer
  • Malte Peters, Chief Research & Development Officer
  • Armin Weidmann, Head-Compliance & Quality Assurance

What is Simon E. Moroney's approval rating as MorphoSys' CEO?

5 employees have rated MorphoSys CEO Simon E. Moroney on Glassdoor.com. Simon E. Moroney has an approval rating of 100% among MorphoSys' employees. This puts Simon E. Moroney in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did MorphoSys IPO?

(MOR) raised $200 million in an IPO on Thursday, April 19th 2018. The company issued 8,300,000 shares at $24.12 per share. Goldman Sachs, J.P. Morgan and Leerink Partners served as the underwriters for the IPO and Berenberg Capital Markets and JMP Securities were co-managers.

What is MorphoSys' stock symbol?

MorphoSys trades on the NASDAQ under the ticker symbol "MOR."

Who are MorphoSys' major shareholders?

MorphoSys' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (0.62%), Millennium Management LLC (0.29%), Morgan Stanley (0.11%), Renaissance Technologies LLC (0.04%), Henry James International Management Inc. (0.03%) and Marshall Wace LLP (0.02%).

Which institutional investors are selling MorphoSys stock?

MOR stock was sold by a variety of institutional investors in the last quarter, including Henry James International Management Inc., Two Sigma Investments LP, Goldman Sachs Group Inc., and Morgan Stanley.

Which institutional investors are buying MorphoSys stock?

MOR stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Renaissance Technologies LLC, Marshall Wace LLP, US Bancorp DE, and Signaturefd LLC.

How do I buy shares of MorphoSys?

Shares of MOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MorphoSys' stock price today?

One share of MOR stock can currently be purchased for approximately $10.03.

How much money does MorphoSys make?

MorphoSys has a market capitalization of $1.37 billion and generates $374.30 million in revenue each year. The company earns $111.82 million in net income (profit) each year or ($1.32) on an earnings per share basis.

How many employees does MorphoSys have?

MorphoSys employs 615 workers across the globe.

What is MorphoSys' official website?

The official website for MorphoSys is www.morphosys.com.

Where are MorphoSys' headquarters?

MorphoSys is headquartered at SEMMELWEISSTR. 7, PLANEGG 2M, 82152.

How can I contact MorphoSys?

MorphoSys' mailing address is SEMMELWEISSTR. 7, PLANEGG 2M, 82152. The company can be reached via phone at (498) 989-9270, via email at [email protected], or via fax at 49-89-8992-7222.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.